Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Safety and efficacy of contemporary catheter ablation for atrial fibrillation patients with a history of cardioembolic stroke in the era of direct oral anticoagulants.

Nishizaki K, Itoh T, Kimura M, Tsushima Y, Shoji Y, Kinjo T, Ishida Y, Sasaki K, Horiuchi D, Sasaki S, Tomita H, Okumura K.

J Cardiol. 2017 Jul;70(1):86-91. doi: 10.1016/j.jjcc.2016.10.001. Epub 2016 Nov 3.

2.

Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.

Kuwahara T, Abe M, Yamaki M, Fujieda H, Abe Y, Hashimoto K, Ishiba M, Sakai H, Hishikari K, Takigawa M, Okubo K, Takagi K, Tanaka Y, Nakajima J, Takahashi A.

J Cardiovasc Electrophysiol. 2016 May;27(5):549-54. doi: 10.1111/jce.12928. Epub 2016 Feb 12.

PMID:
26766541
3.

Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.

Armbruster HL, Lindsley JP, Moranville MP, Habibi M, Khurram IM, Spragg DD, Berger RD, Calkins H, Marine JE.

Ann Pharmacother. 2015 Mar;49(3):278-84. doi: 10.1177/1060028014563950. Epub 2014 Dec 16.

PMID:
25515868
4.

Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.

Tereshchenko LG, Henrikson CA, Cigarroa J, Steinberg JS.

J Am Heart Assoc. 2016 May 20;5(5). pii: e003206. doi: 10.1161/JAHA.116.003206.

5.
6.

Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.

Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbuchel H, Lanz HJ, Mont L, Morillo CA, Smolnik R, Yin OQP, Kautzner J.

Clin Cardiol. 2018 Apr;41(4):440-449. doi: 10.1002/clc.22918. Epub 2018 Apr 17.

7.

Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.

Moseley A, Doukky R, Williams KA, Jaffer AK, Volgman AS.

J Womens Health (Larchmt). 2017 Mar;26(3):214-221. doi: 10.1089/jwh.2016.5892. Epub 2016 Nov 21.

PMID:
27870603
8.

Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.

Stepanyan G, Badhwar N, Lee RJ, Marcus GM, Lee BK, Tseng ZH, Vedantham V, Olgin J, Scheinman M, Gerstenfeld EP.

J Interv Card Electrophysiol. 2014 Jun;40(1):33-8. doi: 10.1007/s10840-014-9888-9. Epub 2014 Mar 19.

PMID:
24643666
9.

Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.

Okishige K, Nakamura T, Aoyagi H, Kawaguchi N, Yamashita M, Kurabayashi M, Suzuki H, Asano M, Shimura T, Yamauchi Y, Sasano T, Hirao K.

J Cardiol. 2017 Jan;69(1):11-15. doi: 10.1016/j.jjcc.2016.04.009. Epub 2016 May 7.

10.

Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.

Hernandez I, Smith KJ, Zhang Y.

Thromb Res. 2017 Feb;150:123-130. doi: 10.1016/j.thromres.2016.10.006. Epub 2016 Oct 15.

PMID:
27771008
11.

Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.

Lee SI, Sayers M, Lip GY, Lane DA.

Int J Clin Pract. 2015 Nov;69(11):1341-8. doi: 10.1111/ijcp.12712. Epub 2015 Aug 3.

PMID:
26234557
12.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

13.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

14.

Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.

Sjögren V, Byström B, Renlund H, Svensson PJ, Oldgren J, Norrving B, Själander A.

PLoS One. 2017 Jul 10;12(7):e0181000. doi: 10.1371/journal.pone.0181000. eCollection 2017.

15.

Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.

Bansal VK, Herzog CA, Sarnak MJ, Choi MJ, Mehta R, Jaar BG, Rocco MV, Kramer H.

Am J Kidney Dis. 2017 Dec;70(6):859-868. doi: 10.1053/j.ajkd.2017.08.003. Epub 2017 Sep 21. Erratum in: Am J Kidney Dis. 2019 Apr;73(4):578-579.

PMID:
28941763
16.

Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).

Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD, Silverman S, Singhal AB, Nicolau JC, SomaRaju B, Mercuri MF, Antman EM, Braunwald E; ENGAGE AF-TIMI 48 Investigators.

Stroke. 2016 Aug;47(8):2075-82. doi: 10.1161/STROKEAHA.116.013540. Epub 2016 Jul 7.

PMID:
27387994
17.

Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants.

Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, Kamikawa S, Komtasubara I, Kusachi S.

Clin Drug Investig. 2016 Oct;36(10):837-48. doi: 10.1007/s40261-016-0435-6.

18.

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.

Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Stevens SM, Weiss JP, Woller SC, Bunch TJ.

Am J Cardiol. 2016 Jul 15;118(2):210-4. doi: 10.1016/j.amjcard.2016.04.039. Epub 2016 May 5.

PMID:
27236255
19.

Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin.

Shin DG, Kim TH, Uhm JS, Kim JY, Joung B, Lee MH, Pak HN.

Yonsei Med J. 2016 Mar;57(2):342-9. doi: 10.3349/ymj.2016.57.2.342.

20.

Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH.

Stroke. 2017 Sep;48(9):2494-2503. doi: 10.1161/STROKEAHA.117.017549. Epub 2017 Jul 17. Review.

PMID:
28716982

Supplemental Content

Support Center